Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
6 participants
INTERVENTIONAL
2006-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Oglemilast for the Prevention of Asthma.
NCT00322283
A Clinical Study of Oglemilast in Patients With Mild to Moderate Persistent Asthma
NCT00859404
Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma
NCT00870584
Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation
NCT01232322
Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)
NCT00367016
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oglemilast followed by placebo
Oglemilast
Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
Placebo followed by Oglemilast
Placebo then Oglemilast
Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oglemilast
Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
Placebo then Oglemilast
Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hyperreactivity to methacholine
* Exhibit positive response to standard allergen skin prick test
Exclusion Criteria
* Asthma exacerbation within 4 weeks
* History of substance abuse
* Active cardiac disease
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Forest Laboratories
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Forest Investigative Site
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GRC-MD-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.